Drugs / BAT5906
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04151212 | Oct 2018 → Feb 2021 | age-related macular degeneration | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04772105 | Oct 2020 → Nov 2023 | diabetic macular edema | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05141994 | Aug 2020 → Sep 2022 | wet macular degeneration | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07515079 | Oct 2024 → Apr 2027 expected | diabetic macular edema | Bio-Thera Solutions | Recruiting | No outcome recorded |
| Phase 3 | NCT05439629 | Jul 2022 → Apr 2025 | wet macular degeneration | Bio-Thera Solutions | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT5906 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05141994 ↗ |
| Route | Intravitreal | “Route of administration: intravitreal injection” NCT04151212 ↗ |